NASDAQ: EPRXEupraxia Pharmaceuticals Inc Stock
$2.90+0.00 (+0%)
Updated May 13, 2024
EPRX Price
$2.90
Fair Value Price
N/A
Market Cap
$103.31M
52 Week Low
$2.48
52 Week High
$3.50
P/E
N/A
P/B
5.29x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.95
Operating Cash Flow
N/A
Beta
0.16
Next Earnings
Jun 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EPRX is good value based on its book value relative to its share price (5.29x), compared to the US Biotechnology industry average (6.01x)
P/B vs Industry Valuation
EPRX's short-term assets ($36.22M) exceed its short-term liabilities ($18.53M)
Short-term Liabilities Financials
EPRX's short-term assets ($36.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more EPRX due diligence checks available for Premium users.
Be the first to know about important EPRX news, forecast changes, insider trades & much more!
EPRX News
Valuation
EPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.29x
Industry
6.01x
EPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EPRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.2M
Profit Margin
0%
Assets to liabilities
Assets
$36.6M
Liabilities
$18.5M
Debt to equity
0.95
EPRX's short-term assets ($36.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EPRX's short-term assets ($36.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
-$6.8k
Financing
$23.2M
EPRX vs Biotech Stocks
Eupraxia Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.